ZURICH (Reuters) - Moderna Inc delivered the latest good news from COVID-19 vaccine developers, saying its experimental vaccine is 94.5% effective in preventing the disease based on interim data from a late-stage trial.
Pfizer Inc. and BioNTech SE on Nov. 9 trumpeted early data indicating their mRNA candidate is more than 90% effective.
Already a subscriber? Log in.
Subscribe to win RM50 Touch 'n Go e-Voucher! More Info
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!